RESIDENTIAL SCHOOL ON MEDICINAL CHEMISTRY:
Biology and Chemistry of Drug Discovery
Drew University, Madison, New Jersey
June 13 – 17, 2011

LECTURES
Strategic Issues in Drug Discovery
Enzyme Inhibition
Receptor Binding Assays
Hit-to-Lead Process in Drug Discovery
Lead Discovery & Modification (2)
Fragment-based Drug Design
Structure-based Drug Design
Drug-like Properties in Drug Discovery
Plasma Protein Binding
Monoclonal Antibodies
Preclinical Toxicology
G-Protein-Coupled Receptors
Kinase Inhibitors
Drugs Affecting ION Channels
Clinical Development

FACULTY
Magid Abou-Gharbia, Ph.D., Temple University
Eugene Cordes, Ph.D., Vertex Pharmaceuticals
Christopher Haber, Ph.D., Pfizer
Craig Lindsley, Ph.D., Vanderbilt University
Richard Silverman, Ph.D., Northwestern University
Miles Congreve, Ph.D., Heptares Therapeutics
Jonathan Greer, Ph.D., Abbott Laboratories
Edward Kerns, Ph.D., Pfizer
George Trainor, Ph.D., Bristol-Myers Squibb
Tina Meng, Ph.D., Amgen
James MacDonald, Ph.D., Chrysalis Pharma
Jeff Reagan, Ph.D., Amgen
William Windsor, Ph.D., Merck
David J. Triggle, Ph.D., SUNY Buffalo
James McLeod, M.D., Merck

SEMINARS
Drug Metabolism for Medicinal Chemists and Biologists
Molecular Modeling
Pharmacokinetics and ADME

FACULTY
John Erve, Ph.D., Novartis
Jonathan Greer, Ph.D., Abbott Laboratories
Cheryl Zimmerman, Ph.D., Univ. of Minnesota

CASE HISTORIES
MK-4305
Eltrombopag
Pazopanib
Saxagliptin
Raltaggravir

FACULTY
Paul Coleman, Ph.D., Merck
Kevin Duffy, Ph.D., GlaxoSmithKline
Philip Harris, Ph.D., GlaxoSmithKline
Jeffrey Robl, Ph.D., Bristol-Myers Squibb
John Wai, Ph.D., Merck